OPKO to Host Symposium to Present Clinical Data on its Long-acting Human Growth Hormone at the 49th Annual Meeting of the Japanese Society for Pediatric Endocrinology

October 08, 2015 8:30am EDT

Download as PDF

MIAMI--(BUSINESS WIRE)--

OPKO Health, Inc. (NYSE: OPK) today announced that the company will host

a symposium at the 49th Annual Meeting of the Japanese Society for

Pediatric Endocrinology and will present the complete 12-month

pharmacokinetic, pharmacodynamic, safety and efficacy data of OPKO’s

weekly long-acting growth hormone (hGH-CTP) in naïve growth hormone

deficient children. The 49th Annual Meeting of the Japanese Society for

Pediatric Endocrinology is taking place in Tokyo, Japan from October

8-10.

The data to be presented include results for 53 naïve growth hormone

deficient children completing twelve months of weekly treatment with

hGH-CTP. This phase 2 study was a one year, dose finding study

administering hGH-CTP to growth hormone deficient children once a week

using Genotropin® as a daily comparator arm. The twelve months data

confirm comparable response of hGH-CTP to daily Genotropin® as reflected

by the twelve months IGF-1SDS profile, annual HV, HV SDS and safety

profile.

OPKO’s symposium will be held on Friday, Oct. 10, 2015 at 1.30pm.

ABOUT OPKO HEALTH

OPKO is a multinational biopharmaceutical and diagnostics company that

seeks to establish industry-leading positions in large, rapidly growing

markets by leveraging its discovery, development and commercialization

expertise and novel and proprietary technologies. For more information,

visit http://www.opko.com .

SAFE HARBOR STATEMENT

This press release contains "forward-looking statements," as that

term is defined under the Private Securities Litigation Reform Act of

1995 (PSLRA), which statements may be identified by words such as

"expects," "plans," "projects," "will," "may," "anticipates,"

"believes," "should," "intends," "estimates," and other words of similar

meaning, including statements regarding expected benefits of hGH-CTP,

whether OPKO's clinical trials for adult and pediatric growth hormone

deficiency will generate data to support marketing approval, whether

hGH-CTP will be successfully developed or commercialized, expectations

regarding the product and its market potential, as well as other

non-historical statements about our expectations, beliefs or intentions

regarding our business, technologies and products, financial condition,

strategies or prospects. Many factors could cause our actual activities

or results to differ materially from the activities and results

anticipated in forward-looking statements. These factors include those

described in our filings with the Securities and Exchange Commission, as

well as the risks inherent in funding, developing and obtaining

regulatory approvals of new, commercially-viable and competitive

products and treatments. In addition, forward-looking statements may

also be adversely affected by general market factors, competitive

product development, product availability, federal and state regulations

and legislation, the regulatory process for new products and

indications, manufacturing issues that may arise, patent positions and

litigation, among other factors. The forward-looking statements

contained in this press release speak only as of the date the statements

were made, and we do not undertake any obligation to update

forward-looking statements. We intend that all forward-looking

statements be subject to the safe-harbor provisions of the PSLRA.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151008005110/en/

OPKO Health, Inc.

Investor Relations, 305-575-4100

or

Media

Contacts

Rooney & Associates

Terry Rooney, 212-223-0689

or

Rooney

& Associates

Marion Janic, 212-223-4017

Source: OPKO Health, Inc.

Released October 8, 2015

email Email Alerts

location_city Company Profile

contact_page Contacts

rss_feed RSS News Feed

account_tree Sitemap